These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16980143)

  • 21. Efficacy and effectiveness approaches in behavioral treatment trials.
    Nash JM; McCrory D; Nicholson RA; Andrasik F
    Headache; 2005 May; 45(5):507-12. PubMed ID: 15953267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence-based interventional pain management: principles, problems, potential and applications.
    Manchikanti L; Boswell MV; Giordano J
    Pain Physician; 2007 Mar; 10(2):329-56. PubMed ID: 17387356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From randomized controlled trials to observational studies.
    Silverman SL
    Am J Med; 2009 Feb; 122(2):114-20. PubMed ID: 19185083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evidence-based dentistry and rating the validity and applicability of research].
    Aartman IH; van Loveren C
    Ned Tijdschr Tandheelkd; 2007 Apr; 114(4):166-71. PubMed ID: 17484413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reporting of adverse events in systematic reviews can be improved: survey results.
    Hopewell S; Wolfenden L; Clarke M
    J Clin Epidemiol; 2008 Jun; 61(6):597-602. PubMed ID: 18411039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised controlled trials in orthopaedic surgery and traumatology: overview of parameters and pitfalls.
    Soucacos PN; Johnson EO; Babis G
    Injury; 2008 Jun; 39(6):636-42. PubMed ID: 18533154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cautionary tales in the clinical interpretation of therapeutic trial reports.
    Scott IA; Greenberg PB
    Intern Med J; 2005 Oct; 35(10):611-21. PubMed ID: 16207261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. External validity: the neglected dimension in evidence ranking.
    Persaud N; Mamdani MM
    J Eval Clin Pract; 2006 Aug; 12(4):450-3. PubMed ID: 16907689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized controlled versus naturalistic studies: a new research agenda.
    Leichsenring F
    Bull Menninger Clin; 2004; 68(2):137-51. PubMed ID: 15262616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gold is not always good enough: the shortcomings of randomization when evaluating interventions in small heterogeneous samples.
    Blair E
    J Clin Epidemiol; 2004 Dec; 57(12):1219-22. PubMed ID: 15617946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges in systematic reviews that evaluate drug efficacy or effectiveness.
    Santaguida PL; Helfand M; Raina P
    Ann Intern Med; 2005 Jun; 142(12 Pt 2):1066-72. PubMed ID: 15968031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study design and "evidence" in patient-oriented research.
    Concato J
    Am J Respir Crit Care Med; 2013 Jun; 187(11):1167-72. PubMed ID: 23725613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Explanatory versus pragmatic trial-based economic evaluations: application to alternative therapies for burns.
    Carayanni V; Tsati E
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):37-48. PubMed ID: 20121563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A scale for distinguishing efficacy from effectiveness was adapted and applied to stroke rehabilitation studies.
    Zettler LL; Speechley MR; Foley NC; Salter KL; Teasell RW
    J Clin Epidemiol; 2010 Jan; 63(1):11-8. PubMed ID: 19740623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pros and cons of pragmatic clinical trials.
    Lurie JD; Morgan TS
    J Comp Eff Res; 2013 Jan; 2(1):53-8. PubMed ID: 24236521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.
    Thorpe KE; Zwarenstein M; Oxman AD; Treweek S; Furberg CD; Altman DG; Tunis S; Bergel E; Harvey I; Magid DJ; Chalkidou K
    J Clin Epidemiol; 2009 May; 62(5):464-75. PubMed ID: 19348971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rating of Included Trials on the Efficacy-Effectiveness Spectrum: development of a new tool for systematic reviews.
    Wieland LS; Berman BM; Altman DG; Barth J; Bouter LM; D'Adamo CR; Linde K; Moher D; Mullins CD; Treweek S; Tunis S; van der Windt DA; Zwarenstein M; Witt C
    J Clin Epidemiol; 2017 Apr; 84():95-104. PubMed ID: 28188898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Explanatory Versus Pragmatic Trials: An Essential Concept in Study Design and Interpretation.
    Merali Z; Wilson JR
    Clin Spine Surg; 2017 Nov; 30(9):404-406. PubMed ID: 29049130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing the design of pragmatic trials: key issues remain.
    Caro JJ; Ishak KJ
    J Comp Eff Res; 2012 Jul; 1(4):319-27. PubMed ID: 24237466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.